List of Excipients in Branded Drug MOTRIN DUAL ACTION WITH TYLENOL

Generic Drugs Containing MOTRIN DUAL ACTION WITH TYLENOL

Company	Ingredient	NDC	Excipient
Kenvue Brands LLC	acetaminophen and ibuprofen	50580-208	CELLULOSE, MICROCRYSTALLINE
Kenvue Brands LLC	acetaminophen and ibuprofen	50580-208	CROSCARMELLOSE SODIUM
Kenvue Brands LLC	acetaminophen and ibuprofen	50580-208	CROSPOVIDONE
Kenvue Brands LLC	acetaminophen and ibuprofen	50580-208	POLYETHYLENE GLYCOL
Kenvue Brands LLC	acetaminophen and ibuprofen	50580-208	POLYVINYL ALCOHOL

What are the Most Frequently-Used Excipients in MOTRIN DUAL ACTION WITH TYLENOL?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	CROSPOVIDONE
1	POLYETHYLENE GLYCOL
1	POLYVINYL ALCOHOL

Motrin Dual Action with Tylenol Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Motrin Dual Action with Tylenol combines acetaminophen 250 mg and ibuprofen 125 mg per caplet. Its commercial value comes from dose convenience, dual analgesic positioning, and brand recognition rather than active-ingredient exclusivity. The principal excipient opportunities are tablet manufacturability, rapid and reproducible dissolution, swallowability, coating performance, packaging stability, and differentiated dosage forms.

What is Motrin Dual Action with Tylenol?

Motrin Dual Action with Tylenol is an over-the-counter combination analgesic marketed in the United States by Kenvue. Each caplet contains:

Attribute	Product detail
Active ingredients	Acetaminophen 250 mg; ibuprofen 125 mg
Dosage form	Oral caplet
Intended users	Adults and children 12 years and older
Labeled dosing	Two caplets every eight hours
Maximum labeled dose	Six caplets in 24 hours
Maximum daily actives	Acetaminophen 1,500 mg; ibuprofen 750 mg
Therapeutic category	Analgesic and antipyretic
Regulatory presentation	OTC Drug Facts labeling
Principal commercial competitors	Advil Dual Action, store-brand acetaminophen/ibuprofen combinations

The product is positioned for temporary relief of minor aches and pains, including headache, backache, toothache, menstrual cramps, muscle aches, arthritis pain and common-cold-related aches. The label carries the standard acetaminophen liver-warning and ibuprofen nonsteroidal anti-inflammatory drug, or NSAID, warnings.[1]

What excipients are used in Motrin Dual Action with Tylenol?

The public product label identifies conventional tablet excipients, including disintegrants, binders, lubricants, coating materials and processing aids. Public labeling should be treated as the controlling source for the marketed composition because excipient grades, coating systems and supplier details are generally not disclosed.

Reported inactive ingredients include the following functional classes:

Excipient function	Likely role in the caplet
Microcrystalline cellulose	Diluent, compression aid and structural matrix
Croscarmellose sodium	Superdisintegrant that promotes tablet breakup
Sodium starch glycolate	Swelling disintegrant
Povidone	Binder that improves granule and tablet strength
Stearic acid	Lubricant
Sodium lauryl sulfate	Wetting agent and dissolution aid
Hypromellose	Film-forming coating polymer
Polyethylene glycol	Plasticizer or coating-process aid
Titanium dioxide	Opacifier and colorant where used
Talc or related mineral coating aid	Anti-tacking and coating-process support where used
Carnauba wax	Polishing or surface-finishing agent where used

The most commercially important excipient architecture is the combination of a compressible filler, two disintegrants, a binder and a wetting agent. That design supports a compact caplet containing two active ingredients with different physicochemical properties.

How does the excipient system support a dual-analgesic tablet?

Acetaminophen and ibuprofen create formulation constraints because they differ in dose, solubility, density, compression behavior and dissolution characteristics. Acetaminophen is present at twice the mass of ibuprofen, while ibuprofen is relatively lipophilic and poorly water-soluble.

A practical formulation strategy must address four performance targets:

1. Uniform distribution of the lower-dose ibuprofen component.
2. Sufficient tablet hardness for packaging and consumer handling.
3. Rapid disintegration without excessive friability.
4. Reproducible dissolution for both active ingredients.

Microcrystalline cellulose and povidone can provide the mechanical strength needed for a caplet format. Croscarmellose sodium and sodium starch glycolate create complementary disintegration mechanisms. Sodium lauryl sulfate can improve wetting of ibuprofen particles, but its concentration must be controlled because excessive surfactant can affect tablet strength, dissolution profiles, taste and gastrointestinal tolerability.

The formulation must also avoid over-lubrication. Excess stearic acid or prolonged lubrication can reduce tablet wettability and slow dissolution. This is particularly relevant for ibuprofen, where hydrophobicity already creates a dissolution challenge.

What excipient strategies could improve the product?

Faster dissolution

A reformulator could evaluate sodium lauryl sulfate alternatives, poloxamers, surfactant-treated ibuprofen, co-processed excipients or particle-size engineering. The objective would be faster wetting without increasing surfactant exposure or creating a new taste burden.

A directly compressible co-processed excipient could reduce process steps and improve blend uniformity. The commercial advantage would be strongest if the formulation achieved faster dissolution while retaining the same caplet size and labeled dose.

Smaller caplets

Two caplets deliver 500 mg of acetaminophen and 250 mg of ibuprofen. Tablet mass can become commercially important because large caplets reduce swallowability and increase packaging volume.

Higher-functionality fillers, roller compaction, spray-dried excipients and optimized particle-size distributions could reduce tablet volume. The main technical risk is loss of hardness or increased capping during high-speed compression.

Improved swallowability

A smoother hypromellose film, rounded caplet geometry, lower tablet edge sharpness and optimized coating friction can improve consumer acceptance. A thinner coating can reduce tablet mass but may reduce moisture protection and visual uniformity.

A gel-forming or lubricious coating could create a meaningful product distinction, although coating claims would need support through consumer testing and regulatory-compliant labeling.

Reduced gastrointestinal burden

Excipients cannot remove the core NSAID risks associated with ibuprofen. They may, however, support a formulation that reduces local irritation through faster dispersion, controlled particle exposure or improved tablet breakup. Any claim implying reduced gastrointestinal injury would require clinical evidence and would raise significant regulatory and liability issues.

Taste and mouthfeel control

The product is swallowed intact, so taste masking is less important than with chewables or orally disintegrating tablets. It becomes commercially important if the company develops liquid, chewable, orally disintegrating or fast-melt versions.

Taste masking could use polymer barriers, ion-exchange resins, lipid coatings or sweetener systems. Ibuprofen’s bitter taste and acetaminophen’s high dose make a palatable chewable formulation technically difficult.

What dosage-form opportunities exist beyond the current caplet?

Dosage form	Commercial opportunity	Primary technical barrier
Smaller caplet	Improved swallowability and portability	Maintaining dose uniformity and dissolution
Gelcap or liqui-gel	Premium positioning and consumer familiarity	Ibuprofen solubilization and shell compatibility
Chewable tablet	Pediatric and adult convenience	Taste masking and dose-size constraints
Orally disintegrating tablet	Rapid-use positioning	High active load and bitter taste
Powder sachet	Flexible dosing and portability	Taste, moisture protection and dose uniformity
Liquid suspension	Pediatric or swallowing-difficulty market	Stability, sedimentation and preservative system
Bilayer tablet	Physical separation of actives or release profiles	Manufacturing complexity and cost
Modified-release format	Longer-duration positioning	Regulatory and clinical substantiation

A bilayer design could separate acetaminophen and ibuprofen during processing or use distinct excipient systems for each active. That approach may improve dissolution control and create a stronger formulation patent position, but it would increase manufacturing complexity.

A liquid or sachet product could expand the addressable market, but the 250 mg/125 mg strength ratio must remain clear. Dose confusion is a material risk because consumers may combine the product with other acetaminophen- or NSAID-containing medicines.

What patents protect Motrin Dual Action with Tylenol?

The core active ingredients do not provide meaningful composition-of-matter exclusivity. Acetaminophen and ibuprofen have been generic medicines for decades, and the basic analgesic properties of the two ingredients are well established.

The relevant intellectual-property categories are:

IP category	Risk assessment
Acetaminophen patent	No meaningful remaining basic-molecule exclusivity
Ibuprofen patent	No meaningful remaining basic-molecule exclusivity
Fixed-dose combination	Potential prior-art and obviousness exposure
Specific excipient composition	Potential protection if unexpected dissolution, stability or tolerability data exist
Bilayer or multilayer tablet	Potential protection for structure and manufacturing process
Coating system	Potential protection if technically distinctive
Manufacturing process	Potential protection for blend uniformity, compression or coating controls
Trademark and trade dress	Primary current brand barrier
Method of use	Limited value where the indication is conventional OTC pain relief

No widely recognized Orange Book patent estate is associated with the basic OTC Motrin Dual Action with Tylenol caplet. OTC monograph products generally do not receive the same Orange Book patent-listing treatment as prescription products approved through an NDA. The commercial barrier is therefore more likely to arise from branding, shelf placement, consumer loyalty, formulation know-how and manufacturing scale than from an active patent covering the marketed combination.[2]

A private patent search could identify formulation or process filings involving fixed-dose acetaminophen/ibuprofen products, but a patent filing alone would not establish enforceability against this specific product.

When does Motrin Dual Action with Tylenol lose exclusivity?

The product has no conventional prescription-drug exclusivity period to expire. The active ingredients are already generic, and competing manufacturers can formulate an acetaminophen/ibuprofen combination if they satisfy applicable FDA requirements.

The practical exclusivity timeline is:

Event	Commercial effect
Historical acetaminophen and ibuprofen patents expire	Generic active ingredients become widely available
OTC combination launch	Creates brand and shelf-positioning advantage
Store-brand product launch	Direct price competition becomes possible
Reformulation or new dosage form	May create limited formulation differentiation
Brand investment and distribution expansion	Sustains non-patent market protection

A competing product does not need to wait for a patent expiration if no enforceable patent covers the specific formulation or if the product uses a non-infringing composition. The relevant regulatory route may be an OTC monograph-compliant product, subject to the status of the applicable monographs and FDA requirements.

What is the FDA and Orange Book status?

Motrin Dual Action with Tylenol is marketed as an OTC analgesic with Drug Facts labeling. Its label identifies the two active ingredients, uses, warnings, directions and inactive ingredients.[1]

The product should not be analyzed as a conventional prescription NDA product. Key consequences include:

• No typical Hatch-Waxman Paragraph IV litigation pathway based solely on the marketed OTC label.
• No conventional prescription exclusivity countdown.
• No expected Orange Book patent estate comparable to a patented prescription drug.
• Greater importance of OTC monograph compliance, labeling, manufacturing controls and product quality.
• Potential regulatory risk if a reformulation changes dosage, release characteristics, indication, population or administration method.

A new dosage form or materially different combination could require a separate FDA regulatory assessment. The commercial objective should be to preserve the established OTC pain-relief positioning while avoiding changes that trigger unnecessary regulatory complexity.

Which companies are challenging the product commercially?

The main competitive threat comes from generic and store-brand combinations rather than branded Paragraph IV challengers.

Advil Dual Action

Advil Dual Action is the closest branded competitor. It uses the same basic active-ingredient concept, acetaminophen and ibuprofen, at the same commonly marketed per-caplet strengths. Competition is driven by brand loyalty, retailer placement, pricing and advertising.

Store-brand combinations

Retailers and generic manufacturers can compete through private-label acetaminophen/ibuprofen caplets. Their principal advantages are lower cost and retailer control over shelf positioning. Their disadvantages are weaker consumer recognition and less investment in national advertising.

Single-ingredient products

Consumers can independently combine acetaminophen and ibuprofen products. This creates a substitution risk but also highlights the convenience value of a fixed-dose product. A combination caplet reduces the number of products a consumer must purchase and may reduce dosing complexity, although labeling must warn against duplicate active ingredients.

What licensing deals affect Motrin Dual Action with Tylenol?

No major public licensing transaction is generally associated with the specific Motrin Dual Action with Tylenol formulation. The product is primarily a branded consumer-health product.

Potential licensing opportunities in this category include:

• Co-processed excipient technologies.
• Ibuprofen solubilization platforms.
• Film-coating systems.
• Taste-masking technologies.
• Gelcap and liquid-fill manufacturing.
• Child-resistant or dose-tracking packaging.
• Digital adherence or dosing systems.

For an excipient supplier, the strongest commercial proposition would combine a measurable technical benefit with a low-change implementation path. A drop-in excipient that preserves existing compression equipment, coating equipment and release specifications is more commercially attractive than a high-performance technology requiring a new production line.

How strong is the formulation and manufacturing IP position?

The basic caplet formulation has moderate to weak apparent patent defensibility because it relies on common excipient classes and well-known analgesic ingredients. A stronger patent position would require a narrower technical feature, such as:

• A defined particle-size relationship between acetaminophen and ibuprofen.
• A specific dissolution profile for both actives.
• A bilayer arrangement that prevents chemical or physical incompatibility.
• A distinctive surfactant-polymer system.
• A coating that improves swallowability while preserving rapid release.
• A process that produces unusually high content uniformity at commercial scale.
• Stability data demonstrating an unexpected advantage.

Trade secrets may be more valuable than patents for blend order, granulation endpoint, lubrication time, compression force, coating parameters and in-process controls. These details are difficult for competitors to identify from the finished product.

What generic launch risks exist?

Generic entry risk is high at the active-ingredient level and moderate to high at the fixed-dose-product level. The most likely launch paths are:

1. A store-brand caplet matching the same strengths.
2. A generic product with a different excipient system and equivalent OTC labeling.
3. A premium generic using a smaller caplet or improved coating.
4. A retailer-exclusive product with aggressive price positioning.
5. A liquid, chewable or sachet product aimed at a different consumer segment.

The principal barriers are manufacturing scale, quality consistency, label compliance, retailer access and consumer trust. Patent litigation is less likely to determine entry timing than it would for a prescription product with listed patents.

What revenue exposure does the product create?

Kenvue does not generally report separate net sales for Motrin Dual Action with Tylenol. Revenue exposure is therefore assessed through the broader Motrin and pain-care portfolios rather than through product-level public financial reporting.[3]

Commercial value is concentrated in:

• Premium pricing versus single-ingredient generics.
• Incremental purchases from consumers seeking convenience.
• Cross-selling within the Motrin and Tylenol brand families.
• Retailer visibility in the pain-relief aisle.
• Seasonal demand for headaches, musculoskeletal pain and cold-related aches.
• Potential line extensions in liquid, gelcap and smaller-caplet formats.

The product is vulnerable to private-label substitution because the active ingredients are familiar and inexpensive. Brand equity and compliance-oriented packaging are the main defenses.

Key Takeaways

• Motrin Dual Action with Tylenol contains acetaminophen 250 mg and ibuprofen 125 mg per caplet.
• The principal excipient strategy is conventional but technically balanced: filler, binder, dual disintegrants, lubricant, wetting agent and film coating.
• The most credible product-development opportunities are smaller caplets, faster dissolution, improved coating performance, gelcaps and palatable alternative dosage forms.
• Basic active-ingredient patents do not provide meaningful current protection.
• The product does not have the typical prescription-drug Orange Book and Paragraph IV risk profile.
• Store-brand and generic fixed-dose combinations are the main competitive threat.
• Formulation patents could be valuable only if supported by narrow technical claims and unexpected performance data.
• Manufacturing know-how may provide stronger practical protection than broad excipient claims.
• Product-level revenue is not publicly disclosed, so exposure must be estimated through the broader Motrin pain-care franchise.

FAQs

Can a generic manufacturer copy the Motrin Dual Action excipient system?

A generic manufacturer can use a different excipient system if it produces a compliant product with the required identity, strength, quality and performance. Exact copying is not necessary unless a valid patent or other enforceable right covers the formulation.

Is ibuprofen solubility the main formulation problem?

Yes. Ibuprofen is relatively poorly water-soluble, so wetting, particle size, granulation and lubricant control can materially affect dissolution. Acetaminophen creates a separate high-dose tablet-load and content-uniformity challenge.

Could a bilayer tablet create stronger patent protection?

Yes, but only if the bilayer structure provides a defensible technical advantage, such as improved stability, dissolution or manufacturing performance. A bilayer format alone may face substantial prior-art and obviousness challenges.

Does a different excipient supplier create a new regulatory product?

Not necessarily. A supplier change may be managed within product-quality and change-control procedures if the formulation and performance remain within established specifications. A material composition or dosage-form change can require a new regulatory assessment.

Is a chewable acetaminophen-ibuprofen product commercially attractive?

It could reach consumers who have difficulty swallowing caplets, but taste masking, high active load, dose clarity and pediatric safety labeling create substantial development risks. A chewable product would need a differentiated consumer benefit to justify its higher formulation complexity.

References

1. DailyMed. (n.d.). Motrin Dual Action with Tylenol: Acetaminophen and ibuprofen tablet, film coated. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Kenvue Inc. (2024). Annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission. https://www.sec.gov/

4. U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/otc-monograph-reform

5. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.ecfr.gov/